FDA NEWS

Radiology-centers chain is in default, FDA says - Baltimore Sun
A regional chain of radiology centers and its owner are in default on $1.1 million in fines for performing mammograms after one of its facilities lost its certification to perform the procedure because of equipment problems, according to documents
Source: www.baltimoresun.com

UPDATE 1-Adolor: FDA lifts hold on bowel drug; GSK may exit deal - Reuters
July 3 (Reuters) - Adolor Corp (ADLR.O: Quote , Profile , Research , Stock Buzz ) said U. S. health regulators lifted a clinical hold on its drug Entereg, which is being developed to treat bowel dysfunction in patients on opioid therapy, but said
Source: www.reuters.com

FDA lifts clinical hold on Adolor bowel drug - CNN Money
NEW YORK (Associated Press) - Adolor Corp. said Thursday the Food and Drug Administration has lifted its clinical hold on the company's Entereg drug in chronically constipated patients taking opioid pain drugs. The drug is being developed in
Source: money.cnn.com

Abbott rises after FDA approves Xience V stent - MSN MoneyCentral
NEW YORK (AP) - Shares of Abbott Laboratories rose Thursday after regulators approved its drug-coated Xience V stent for sale. The Food and Drug Administration approved the stent late Wednesday, and Abbott expects it to take between 25 percent and 30
Source: news.moneycentral.msn.com

Adolor gets FDA nod to resume Entereg testing - Philadelphia Inquirer
The Food and Drug Administration said Adolor Corp. could resume clinical testing of its drug Entereg to treat bowel discomfort commonly associated with use of opioid painkillers, the Exton company said today. Development had been halted in April 2007
Source: www.philly.com